NEW YORK — Camber Pharmaceuticals closed 2025 with strong operational and portfolio momentum and is entering 2026 positioned for continued expansion, citing a robust pipeline, rising ANDA activity, and growing presence across specialty and oncology categories.
Backed by parent company Hetero, Camber reported a year marked by broad generic launches and multiple specialty and oncology introductions, reinforcing its focus on access, affordability, and supply reliability in the U.S. market.
Key 2025 highlights include:
- Expanded headcount by 12 percent
- Filed 40 ANDAs and received 43 ANDA approvals
- Participated in more than 60 trade events and industry conferences
- Executed a successful Day-1 launch of eltrombopag
“These accomplishments reflect the strength of our organization, the dedication of our team, and the ongoing commitment of our parent company, Hetero, to develop and deliver high-quality, life-saving medicines to the U.S. market,” said Kon Ostaficiuk, president of Camber Pharmaceuticals. “We remain focused on exceeding expectations every day for our patients, customers, partners, and associates.”
Looking ahead, Camber expects 2026 to be a year of accelerated opportunity. The company anticipates more than 35 new product launches across its specialty and generic oncology portfolio, supported by a disciplined development pipeline. Camber also projects 43 ANDA approvals and 40 ANDA filings in the year ahead.
“Our success is driven by the dedication of our associates, the trust of our customers, and the strong partnerships we’ve built across the industry,” said Scott Hettenhausen, vice president of sales. “With this foundation in place, we are confident that 2026 will be another impactful year for Camber.”
